In our meta-analysis, the NSCLC patients in five studies were divided into the Ang-2 H (high expression) group and the Ang-2 L (lower expression) group via the Ang-2 level, and the overall survival in both groups was calculated [22, 31, 36–38]. This evidence concerns the gene ANGPT2 and non-small cell lung carcinoma.